Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) [prostate cancer vaccine] Plus the Immunological Adjuvant Alhydrogel: A Trial Studying RsPMSA Doses.
Phase of Trial: Phase I
Latest Information Update: 06 Jan 2012
At a glance
- Drugs Aluminium hydroxide (Primary) ; Prostate cancer vaccine (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 06 Jan 2012 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
- 06 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.